Clinical Trial Search

Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants

Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants

Primary: Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review — 37.6; 22.7 weeks — p=0.012

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Progression-Free Survival (PFS) — 4.8; 3.7; 1.8 months — p=<0.0001

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Progression Free Survival (PFS) — 15.6; 6.2 Months — p=< 0.0001

Primary: Objective Response Rate (CR + PR) — 46.7 percentage of participants

Primary: Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC) — 29.9 percentage of participants

Primary: Overall Response Rate (ORR) — 61 percentage of participants

Primary: Overall Response Rate — 92 percentage of patients

Primary: Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria — 71; 82 percentage of…

Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Objective Response Rate (ORR) — 8.3; 39.0; 64.5; 71.4 percentage of participants

Primary: Percentage of Participants Achieving Response — 67.6 percentage of participants with response

Primary: Percentage of Participants Who Achieve Disease Control Rate (DCR) Which Includes Complete Response (CR), Complete Response Unconfirmed (CRu), Partial Response (PR) or…

Primary: Overall Response Rate (ORR) As Assessed By Independent Review Committee — 72 Participants — p=<.0001

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B — 1; 0; 0; 2 Participants

Primary: Progression-Free Survival (PFS) — 8 years

Primary: Percentage of Participants With Objective Response (OR) Per the Lugano Classification According to Independent Radiology Review Committee (IRRC) in Cohort 1 — 91…

Primary: Overall Response Rate (ORR) — 8.6 percentage of participants

Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants

Primary: Percent of Participants With Best Overall Objective Response or Complete Response/Partial Response (CR/PR) — 89 percentage of participants

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Overall Survival and Progression Free Survival — 73 percentage of patients